Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004091 | 0.90 | MEN1 (0.43) | EPHX2GAAHTTKDM4ENPSR1 | |
| SCHEMBL3008378 | 0.89 | EPHX2 (0.47) | EPHX2GAAHTTKDM4ENPSR1 | |
| SCHEMBL3013317 | 0.87 | NPSR1 (0.51) | HTTKDM4ENPSR1TSHRALDH1A1 | |
| SCHEMBL3648733 | 0.86 | HTT (0.39) | EPHX2GAAHTTKDM4ENPSR1 | |
| SCHEMBL3001238 | 0.86 | NPSR1 (0.43) | GAAKDM4ENPSR1TSHRALDH1A1 | |
| SCHEMBL3010689 | 0.86 | NPSR1 (0.43) | EPHX2GAAKDM4ENPSR1TSHR | |
| SCHEMBL3013128 | 0.86 | KDM4E (0.44) | EPHX2GAAKDM4ENPSR1TSHR | |
| SCHEMBL3015848 | 0.86 | SMN1; SMN2 (0.41) | GAAKDM4ENPSR1ALDH1A1FPR2 | |
| SCHEMBL3019449 | 0.86 | EPHX2 (0.43) | EPHX2GAAHTTMAPK1RAB9A | |
| SCHEMBL3017406 | 0.85 | EPHX2 (0.44) | EPHX2GAANPSR1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | EPHX2 4409/4885GAA 110/4885HTT 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.